• roche logo

Cervical Cancer Products

CINtec® PLUS Cytology: optimizing triage in cervical screening

The goal of screening is to avoid misdiagnosis and the over- or under-treatment it causes. CINtec®PLUS Cytology gives a simple, objective result physicians can use to manage their patients accurately. CINtec® PLUS Cytology:

  • Helps ensure women are not lost to follow-up
  • Reduces both the number and frequency of follow-up visits required
  • Gives women clear answers and certainty in their test results

 

Be certain: Improve patient management based on more information, sooner

CINtec® PLUS Cytology, used in combination with the cobas® HPV Test and CINtec Histology, offers clinicians and labs powerful support to aid clinical patient care decisions for women identified as at-risk for cervical disease. The dual-stain biomarker technology included in the CINtec® PLUS Cytology test detects the simultaneous presence within a single cell of the two biomarkers -- p16 and Ki-67. This abnormality is associated with HPV infections that are transforming and can, if left untreated, progress to pre-cancer or cancer. A positive result of these two biomarkers in a single cell signals that a woman is more significantly at risk for disease.

The ability of CINtec® PLUS Cytology to distinguish those women who are at higher risk for cervical disease provides labs, clinicians and women, in conjunction with the physician’s assessment of patient screening history, other risk factors, and professional guidelines information, to guide patient management. This could reduce the number and frequency of follow-up visits, saving worry, time and money.

The Roche Cervical Cancer Portfolio delivers the optimal screening and triage strategy.1

Morphology based diagnosis with Pap cytology is subject to interpretive variability and lacks diagnostic accuracy. HPV DNA testing is the most sensitive screening method, but diagnostic accuracy improves with triage testing of HPV positive test results. In short, clinical outcomes improve when the cobas® HPV test and CINtec® PLUS Cytology are used together. 

Performance of cobas® HPV and CINtec® PLUS Cytology (≥CIN3; age 25+)

 


Sources: Wright et al., Gyn Oncol 2017. Castle, P.E., Stoler, M.H., Wright, T.C. Jr., et al. (2011). Lancet Oncology, 12, 880-890.
*cobas® HPV 16/18 genotyping and CINtec® PLUS Cytology triage of women with other 12 hrHPV

 

CINtec® PLUS Cytology can objectively triage abnormal cytology screening results

Identify women with transforming HPV infections who have ASC-US or LSIL Cytology screening results and will benefit most from immediate colposcopy follow-up.


 

CINtec® PLUS Cytology outperforms Pap cytology as the triage test for HPV(+) screening results

Improved cervical cancer screening strategy: HPV primary screening with the cobas® HPV DNA test. Triage HPV(+) results with the CINtec® PLUS Cytology test demonstrates high sensitivity and specificity to detect transforming HPV infections and helps avoid unnecessary colposcopy for women who do not need it.

*For HPV16/18+ use as additional information in conjunction with the physician’s assessment of patient screening history, other risk factors, and professional guidelines to guide patient management.


 

An objective biomarker test to help triage Pap negative/HPV(+) co-testing results

Improve management of women with Pap cytology negative/HPV(+) results: In co-testing, CINtec® PLUS Cytology provides immediate and actionable results to help reduce the number of women lost to follow-up testing.

*For HPV16/18+ use as additional information in conjunction with the physician’s assessment of patient screening history, other risk factors, and professional guidelines to guide patient management.



Triage of HPV(+) screening results: CINtec® PLUS Cytology vs. Pap Cytology

 



 

Be certain with CINtec® PLUS

Learn more about Roche’s CINtec® PLUS Cytology and how it provides a strong indicator of the presence of transforming HPV infections.

 

Get detailed CINtec® PLUS Cytology laboratory system information. 

 

Learn More


 

References

  1. Castle, P.E., Stoler, M.H., Wright, T.C. Jr., et al. (2011). Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncology, 12, 880-890.